Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

Inclusion Criteria: * Diagnosis of small cell neuroendocrine carcinoma based on either histology or cytology with radiologically-confirmed progressive disease. * Participants should have received first-line chemotherapy and may have had up to two prior chemotherapy regimens. Radiation therapy may have been part of the permitted prior therapy. * Participants with brain metastases will be allowed if they have been treated with surgery and/or radiation therapy more than 21 days prior, are asymptomatic, and are stable for at least one week off steroids. * 18 years of age or older * ECOG Performance status of 0, 1 or 2 * Ability to swallow and retain oral medication * Disease must be measurable according to RECIST 1.1 * Adequate organ function as defined in the protocol Exclusion Criteria: * Prior malignancy except for participants that have been disease-free for 3 years or with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma * History or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for one week prior to first dose of study drug. * Clinically significant gastrointestinal abnormalities * Presence of uncontrolled infection * Prolongation of corrected QT interval (QTc) \> 480msecs * History of any one or more of the following cardiovascular conditions within the past 6 months: cardiac angioplasty or stenting; myocardial infarction; unstable angina; symptomatic peripheral vascular disease; Class III or IV congestive heart failure * Poorly controlled hypertension * History of cerebrovascular accident including transient ischemic attack, pulmonary embolism or insufficiently treated deep venous thrombosis within the past 6 months * Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture or ulcer * Evidence of active bleeding or bleeding diathesis * Hemoptysis in excess of 2.5mL within 6 weeks of first dose of study drug * Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures * Use of any prohibited medication within the timeframes listed in the protocol * Use of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study drug * Prior use of an investigational or licensed drug that targets VEGF or VEGF receptors * Is now undergoing and/or has undergone in the 14 days immediately prior to first dose of study drug, any cancer therapy * Any ongoing toxicity from prior anti-cancer therapy that is \> Grade 1 and/or that is progressing in severity * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib